GSTM1 and cancer: A similar threshold was also found by Kapacee et al., in their series of 148 anal cancer patients treated CT-RT within the ACT-II trial (50.4 Gy/28 fractions delivered over 38 days concomitant to 5-FU and either MMC or DDP), where a pre-treatment Hb level < 13 g/dl was found to predict for lower distant metastasis and cancer-specific survival (p < 0.05) [26].